Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2011 Jun;50(5):630-5.
doi: 10.3109/0284186X.2011.572913. Epub 2011 Apr 18.

Clinical Outcome With Bevacizumab in Patients With Recurrent High-Grade Glioma Treated Outside Clinical Trials

Affiliations
Multicenter Study

Clinical Outcome With Bevacizumab in Patients With Recurrent High-Grade Glioma Treated Outside Clinical Trials

Silvia Hofer et al. Acta Oncol. .

Abstract

Background: Patients with recurrent high-grade glioma (HGG) have a poor prognosis and there is no defined standard of care. High levels of vascular endothelial growth factor (VEGF) expressed in HGG make the anti-VEGF monoclonal antibody bevacizumab (BEV) of particular interest.

Patients and methods: In an ongoing registry data were collected from patients who have received BEV for the treatment of recurrent HGG. The primary objective was the identification of any clinical benefit as assessed by change in Karnofsky Performance Score (KPS), decreased steroid use and duration of treatment.

Results: Two hundred and twenty-five patients with HGG were included (176 glioblastoma; 49 anaplastic glioma; median age 52 years). KPS improved in 10% of patients and remained stable in 68%. Steroids were stopped in 37.6% of patients. Median duration of treatment was 5.5 months; 19.1% of patients were treated for more than 12 months. Median overall survival from beginning of BEV treatment was 8.5 months. At the time of analysis, 169 patients (75.1%) had died and 56 patients (24.9%) were alive. Only 21 patients (9.3%) discontinued treatment due to toxicity.

Conclusions: Our data reveal valuable palliation with preservation of KPS and an option for steroid withdrawal in patients treated with BEV, supporting the role of this therapy in late-stage disease.

Similar articles

See all similar articles

Cited by 12 articles

See all "Cited by" articles

Publication types

MeSH terms

LinkOut - more resources

Feedback